论文部分内容阅读
目的:观察补脾强力胶囊治疗重症肌无力(MG)Ⅰ、Ⅱa型的临床疗效。方法:将75例MGⅠ、Ⅱa型患者随机分为2组。对照组30例予强的松30～50mg,4周后逐步递减直至停服;溴吡斯的明每次30～60mg,每天2～3次,儿童酌减。治疗组45例在对照组基础上加用补脾强力胶囊3～5粒,每天3次。连续观察1年后统计疗效。结果:愈显率治疗组71.1%,对照组43.3%,2组比较,差异有显著性意义(P<0.05);总有效率治疗组88.9%,对照组73.3%,2组比较,差异无显著性意义(P>0.05)。2组电位衰减百分率比较,差异无显著性意义(P>0.05)。停药半年后随访,治疗组复发人数为2/32,对照组为5/21;治疗组无1例出现不良反应,对照组出现向心性肥胖5例,骨关节痛3例。结论:补脾强力胶囊对重症肌无力Ⅰ、Ⅱa型患者有较好的远期疗效,复发率低,有潜在减轻激素类药物毒副作用的效应。
Objective: To observe the clinical efficacy of “Bupi Qiangli Capsule” in the treatment of type Ⅰ and Ⅱ a myasthenia gravis (MG). Methods: 75 patients with MG Ⅰ and Ⅱ a were randomly divided into two groups. Control group, 30 cases of prednisone 30 ~ 50mg, 4 weeks after the gradual decline until stopped taking; bromopyrazine Ming every 30 ~ 60mg, 2 or 3 times a day, children reduce it. Treatment group, 45 cases in the control group based on the use of spleen Qiangli capsules 3 to 5 capsules 3 times a day. Continuous observation of 1 year after the statistical effect. Results: The cure rate was 71.1% in the treatment group and 43.3% in the control group. There was significant difference between the two groups (P <0.05). The total effective rate was 88.9% in the treatment group and 73.3% in the control group. There was no significant difference between the two groups Sexual significance (P> 0.05). There was no significant difference between the two groups (P> 0.05). Six months after discontinuation, the number of relapse in the treatment group was 2/32 and in the control group was 5/21. No adverse reactions were observed in the treatment group. Five cases of central obesity and three cases of osteoarthritis were found in the control group. Conclusion: Bupi Qiangli Capsule has good long-term curative effect on patients with myasthenia gravis type Ⅰ and type Ⅱa with low recurrence rate and potentially reducing the side effects of hormonal drugs.